Fiche publication
Date publication
juin 2021
Journal
The British journal of dermatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
,
Dr NARDIN Charlée
Tous les auteurs :
Guillaume T, Puzenat E, Popescu D, Aubin F, Nardin C
Lien Pubmed
Résumé
Cemiplimab-rwlc (CEMI), a programmed cell death protein 1 (PD-1) inhibitor, has demonstrated its efficacy for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) patients that has never been reported with chemotherapy and is currently recommended for the first-line treatment of patients with advanced CSCC by the European guidelines . However, real-life data and long-term survival data are lacking.
Référence
Br J Dermatol. 2021 Jun 9;:
